In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Access

Set Alert for Market Access

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Europe Germany

US Biosimilars Enjoy A Year Of Firsts In 2021

While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.

Outlook 2022 Market Access

Listen Up! Big Things Happening In The World Of Audiology

From innovation to legislation, the US audiology market is being shaped by cutting-edge technology from device makers and legislation from the Biden administration to get more hearing aids to those that need them.

Outlook 2022 Commercial

New Government Could Increase Pricing Pressures In Germany

Alexander Natz, secretary general of EUCOPE, warns that changes to a pricing and reimbursement system that has so far worked well, particularly for orphans, could dissuade advanced therapy medicinal products manufacturers from launching in Germany.

Europe Market Access

Mind The Maturity Gap: Medtechs Must Improve Digital And Omnichannel Uptake

Boston Consulting Group began writing the third iteration of its report on next-generation commercial models to meet evolving medtech customer needs before COVID struck. But it findings and recommendations were even more relevant once the report – dubbed Milkman 3.0  ̶  was finally released in spring 2021, when learnings from the pandemic were being factored in by the medtech industry.

Market Access Business Strategies

The Oslo Medicines Initiative: Keeping The Equitable Access Dream Alive

One year on from its creation in 2020, a European project with a “new vision for collaboration between the public and private sectors” has set its sights on getting stakeholders across the medicines sector to make firm promises on ensuring equitable patient access to costly new drugs.

Norway Market Access

Medicare, Alzheimer’s Drugs And The Single Payer Effect

US biopharma stakeholders are getting a taste of how a single payer health care system can shape the fate of a new treatment with Medicare’s national coverage determination for amyloid-directed Alzheimer’s drugs including Biogen/Eisai’s Aduhelm.

United States Market Access

Medtechs Must Gear Up For New China Data Protection Rules

China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.

China Market Access

Payers, Providers And The Digital Transformation Imperative

As the threat of digital insurgents grows, traditional payers and providers will need to leverage advanced technologies to address core issues facing the US health care system. 

Digital Health Market Access

Is Now The Time To Build In China?

Deciding whether to build or rent development and commercial capabilities in China requires a deep understanding of the changing Chinese market. Individual product characteristics, and a management team’s tolerance for risk, should be used to determine which model can deliver the best results.

China Strategy

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Coronavirus COVID-19 Leadership

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Market Access Medical Device
See All
UsernamePublicRestriction

Register